PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.47%
Revenue growth above 1.5x ADI's 2.26%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
13.31%
Gross profit growth above 1.5x ADI's 3.05%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
37.52%
EBIT growth above 1.5x ADI's 8.86%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-6.84%
Negative operating income growth while ADI is at 8.86%. Joel Greenblatt would press for urgent turnaround measures.
-4.70%
Negative net income growth while ADI stands at 7.15%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-5.08%
Negative EPS growth while ADI is at 7.55%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3.45%
Negative diluted EPS growth while ADI is at 7.69%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.63%
Share reduction while ADI is at 0.54%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.54%
Reduced diluted shares while ADI is at 0.62%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.31%
Maintaining or increasing dividends while ADI cut them. John Neff might see a strong edge in shareholder returns.
70.77%
Positive OCF growth while ADI is negative. John Neff would see this as a clear operational advantage vs. the competitor.
77.99%
Positive FCF growth while ADI is negative. John Neff would see a strong competitive edge in net cash generation.
100.90%
10Y revenue/share CAGR above 1.5x ADI's 53.39%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
13.95%
Positive 5Y CAGR while ADI is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
-6.30%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
254.02%
10Y OCF/share CAGR above 1.5x ADI's 125.12%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
30.17%
5Y OCF/share CAGR above 1.5x ADI's 5.37%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-5.66%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
120.73%
Net income/share CAGR at 50-75% of ADI's 164.30%. Martin Whitman might question if the firm’s product or cost base lags behind.
32.93%
5Y net income/share CAGR above 1.5x ADI's 19.44%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-20.90%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
51.69%
10Y equity/share CAGR at 50-75% of ADI's 73.79%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
30.26%
Below 50% of ADI's 82.47%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
19.84%
Below 50% of ADI's 47.55%. Michael Burry suspects a serious short-term disadvantage in building book value.
1205.79%
Dividend/share CAGR of 1205.79% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
179.73%
5Y dividend/share CAGR above 1.5x ADI's 69.71%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
132.68%
3Y dividend/share CAGR above 1.5x ADI's 53.39%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
2.21%
AR growth well above ADI's 3.45%. Michael Burry fears inflated revenue or higher default risk in the near future.
0.35%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.79%
Negative asset growth while ADI invests at 5.09%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.48%
Under 50% of ADI's 3.53%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.08%
We’re deleveraging while ADI stands at 15.08%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-5.40%
Our R&D shrinks while ADI invests at 0.65%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.27%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.